You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Baseline demographic and clinical features of 200 chronic hepatitis C patients with interferon-alpha therapy

From: High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

  Total 3-MU group† No. (%) 6-MU group‡ No. (%)
Patient Number 200 76 124
Gender    
Male 103 34(44.7) 69(55.6)
Female 97 42(55.3) 55(44.4)
Age (year)   47.3 ± 10.4 45.3 ± 11.7
History of transfusion    
No 141 56(73.7) 85(68.5)
Yes 59 20(26.3) 39(31.5)
Liver histopathology    
   Total score of necroinflammatory activity 4.48 ± 2.56 4.23 ± 2.46
   Fibrosis score    
F3–4 70 30(39.5) 40(32.3)
F0–2 130 46(60.5) 84(67.7)
Pretreatment ALT value (U/L) 117.4 ± 102.8 104.1 ± 95.4
Pretreatment HCV RNA level (log equivalent/mL) 5.97 ± 0.59 6.01 ± 0.68
HCV genotype    
   1b 80 27(35.5) 53(42.7)
   Non-1b 120 49(64.5) 71(57.3)
Interferon preparation    
   Recombinant IFN-α-2a 37 10(13.2) 27(21.8)
   Recombinant IFN-α-2b 95 36(47.4) 59(47.6)
   Lymphoblastoid IFN-α-n1 68 30(39.5) 38(30.6)
  1. † 3-MU group: interferon-α 3 million units thrice weekly for 24 weeks.
  2. ‡ 6-MU group: interferon-α 6 million units thrice weekly for 24 weeks.